Vaccination in Immunocompromised and Special Conditions

Vaccination of immunocompromised hosts and people with special conditions confronts two challenges at once: these patients are at higher risk of severe infection, yet their impaired immune systems may respond poorly to vaccines and, in some cases, cannot safely receive live vaccines. Immune status, the cause and depth of immunosuppression, and the timing of vaccination relative to therapy therefore become decisive considerations.

Definition

Vaccination in immunocompromised and special conditions is the tailoring of immunization for people whose immune defences are impaired by disease or treatment, balancing their elevated infection risk against reduced vaccine responses and constraints on the use of live vaccines.

Scope

The topic covers who is considered immunocompromised (including transplant recipients, people receiving immunosuppressive therapy, those with HIV or primary immunodeficiency, and patients with certain chronic conditions), why live vaccines are generally avoided in significant immunosuppression, why responses are often blunted, and the principle of timing vaccination around therapy. It is a reference overview and does not give specific vaccine lists, contraindication thresholds, or dosing.

Core questions

• Why are live vaccines generally avoided in significant immunosuppression?
• Why do immunocompromised hosts often respond less well to vaccines?
• How does the timing of vaccination relative to immunosuppressive therapy matter?
• How can household and contact (cocoon) vaccination help protect these patients?

Key concepts

• Immunocompromised host
• Live versus non-live vaccine safety
• Impaired vaccine immunogenicity
• Timing relative to immunosuppressive therapy
• Transplant and HIV-related vaccination
• Cocooning of close contacts

Mechanisms

Two mechanisms dominate. First, live attenuated vaccines rely on limited replication of a weakened organism; when immune control is severely impaired, that organism can replicate uncontrolled and cause disease, which is why such vaccines are generally avoided in significant immunosuppression. Second, the same immune impairment that raises infection risk also reduces the magnitude and durability of responses to non-live vaccines, so protection may be partial and may need to be supported by timing: vaccinating before planned immunosuppression, or during periods of relatively preserved immune function, tends to yield better responses. Protecting close contacts through their own vaccination reduces the chance that household members transmit infection to the vulnerable host. The development of non-live alternatives, such as the adjuvanted subunit zoster vaccine, has expanded options for these patients.

Clinical relevance

Knowing that immune status governs both vaccine safety and response explains why immunocompromised patients require individualised, often specialist-guided immunization plans and why contraindications differ from those in healthy people. This entry presents the principles and evidence for reference and education; decisions about which vaccines, when, and for whom are made under current guidelines and specialist clinical assessment.

Epidemiology

Immunocompromised populations, including the growing numbers of transplant recipients and people on biologic or other immunosuppressive therapies, experience higher rates of severe and recurrent vaccine-preventable infections such as herpes zoster, pneumococcal disease, and influenza. This burden is the impetus for dedicated guidance, most prominently the IDSA clinical practice guideline for vaccination of the immunocompromised host.

History

As immunosuppressive medicine and transplantation expanded, the need for systematic guidance on vaccinating these patients grew, culminating in dedicated syntheses such as the 2013 IDSA guideline. The arrival of effective non-live vaccines, including the adjuvanted herpes zoster subunit vaccine, broadened the immunization options available to immunocompromised hosts who cannot receive live vaccines.

Debates

Defining the threshold of immunosuppression at which live vaccines become unsafe

Immunosuppression spans a spectrum, and where the line falls between caution and contraindication for live vaccines depends on the agent, dose, and disease, remaining a matter of judgement and evolving evidence.

Best timing of vaccination around immunosuppressive therapy

Vaccinating before therapy generally yields stronger responses, but disease urgency often forces vaccination during treatment, and the optimal sequencing is an active area of study.

Key figures

• Lorry Rubin
• Per Ljungman
• Jay Fishman

Seminal works

• rubin-2013
• fishman-2017

Frequently asked questions

Why can't some immunocompromised people receive live vaccines?

Live vaccines contain weakened but replicating organisms; if the immune system is too impaired to control them, the vaccine organism could itself cause illness, so live vaccines are generally avoided in significant immunosuppression.

Does vaccinating family members help protect an immunocompromised patient?

Yes; immunizing close contacts (sometimes called cocooning) lowers the chance that household members catch and pass on an infection to the vulnerable person, who may respond poorly to vaccines themselves.